AbbVie Inc. (ABBV) - Moat Analysis

Business Model

25%

3.2/5

3.22

AbbVie has durable, non-discretionary branded-drug revenue with patent-protected multi-year visibility, but the portfolio remains concentrated in immunology (~50% of FY2025 revenue) and heavily US-centric (~76%). The successful Humira-to-Skyrizi/Rinvoq pivot demonstrates the franchise can reinvent itself, but future LoE events create inherent step-down risk that caps predictability.

Sub-dimension

Summary

Score

Revenue Predictability30%

3.25

Forward visibility of revenue: backlog, contracts, retention

3.25

Summary

Prescription patterns and payer formulary cycles give multi-quarter visibility, and FY2025 revenue grew 8.6% to $61.2B with management guiding $67B and ~9.5% growth for FY2026. However, scheduled loss-of-exclusivity events (Humira -26% in FY2025) create structural step-downs, capping predictability below contract-backlog peers.

3.25

Product Diversification10%

2.75

Diversification across product lines, segments, and customers

2.75

Summary

Immunology represented ~$30.4B of FY2025's $61.2B revenue (~50%), with Skyrizi+Rinvoq alone at ~42%. Oncology, neuroscience (Botox, Vraylar, Vyalev), and aesthetics add diversification acquired via Allergan, but concentration in a single therapeutic area remains elevated.

2.75

Geographic Diversification15%

2.50

Distribution across regions and home-market dependence

2.50

Summary

The United States generated ~$43.0B of FY2024 revenue (76.4%), with non-US at only ~23.6%. This heavy home-market dependence exposes AbbVie disproportionately to US payer policy, IRA negotiation, and patent law, and compares unfavorably to more globally balanced large-cap pharma peers.

2.50

Scalability20%

3.25

Ability to grow revenue without proportional cost increases

3.25

Summary

Branded pharma has inherently high gross margins because incremental units of small-molecule and biologic doses carry low marginal production cost, but $5B+ annual M&A outlays and R&D stepped up ~$1B in 2025 to fund 90 clinical programs absorb much of the operating leverage. Scalability is structural but not dramatic.

3.25

Revenue Quality25%

3.50

Nature of the revenue: contractual vs transactional, defensive vs discretionary

3.50

Summary

Revenue is mission-critical (autoimmune, oncology, Parkinson's indications are non-discretionary) and supported by long patent runways, but it is transactional prescription-by-prescription rather than contracted subscription. Payer reimbursement and formulary access, not consumer choice, drive stickiness.

3.50

Competitive Advantages

40%

3.2/5

3.21

The moat is anchored in biologic/toxin manufacturing complexity, a 90-program R&D pipeline, and IL-23/JAK class leadership (Skyrizi, Rinvoq). Brand equity in Humira and Botox is iconic but brand rarely translates into consumer-style pricing premium in prescription drugs. Network effects are effectively absent, and switching costs are only moderate once patents expire.

Sub-dimension

Summary

Score

Pricing Power30%

3.25

The company's ability to raise prices without losing customers

3.25

Summary

3.25

Switching Costs20%

3.00

How costly it is for customers to switch to a competitor

3.00

Summary

3.00

Network Effects20%

2.00

Whether the product becomes more valuable as more users join

2.00

Summary

2.00

Brand Strength15%

3.50

Degree to which brand drives premium pricing and loyalty

3.50

Summary

3.50

Innovation Barrier15%

4.25

How difficult it is for competitors to replicate the core technology

4.25

Summary

4.25

Full analysis requires login